Angiogenesis in pterygium: Morphometric and immunohistochemical study

Marcovich, Arie; Morad, Yair; Sandbank, Judith; Huszar, Monica; Rosner, Mordechai; Pollack, Ayala; Herbert, Mehrdad; Bar‐Dayan, Yaron

doi:10.1076/ceyr.25.1.17.9959

Cited by 87 publications

(55 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The result of the presented study contradicts previous reports, [29][30][31][32] which demonstrated higher VEGF expression levels in pterygium compared to normal conjunctiva. We must notice that with the exception of the study of Van Setten et al 32 and Marcovich et al, 29 all other studies focus on the overexpression of VEGF in epithelial and vascular endothelial component of pterygium compared to normal conjunctivae. We emphasized in contrast to previous observers that the stromal compartment of pterygium presented a statistically significant higher expression compared to normal tissue.…”

Section: Discussioncontrasting

confidence: 99%

Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1

Aspiotis

Tsanou

Gorezis

et al. 2006

Eye

101

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 99%

Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1

Aspiotis

Tsanou

Gorezis

et al. 2006

Eye

101

View full text Add to dashboard Cite

“…-------------------------------------------------produced by conjunctival fibroblasts, leading to increased angiogenesis which is a characteristic of pterygium (6). VEGFA expression examined with qRT-PCR in the present study was significantly higher in pterygium compared with normal conjunctiva, which is in agreement with previous immunohistochemical reports (17,18). Furthermore, the significant association between postoperative recurrence and VEGFA expression detected in the present study implies that VEGFA may be involved in the clinical behavior of pterygium apart from its pathogenesis.…”

Section: Discussionsupporting

confidence: 92%

Growth factor expression in ophthalmic pterygia and normal conjunctiva

Detorakis

Zaravinos²,

Spandidos³

2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. The expression of growth factors in ophthalmic pterygium and phenotypically normal conjunctiva was examined and correlated with the clinical findings. Fifteen specimens of ophthalmic pterygia and 8 specimens of phenotypically normal conjunctiva were examined. Total RNA was extracted from all specimens and mRNA levels for transforming growth factor (TGFB1), vascular endothelial growth factor (VEGFA), basic fibroblast growth factor (FGF2), epidermal growth factor (EGF) and insulin-like growth factor (IGF1) were measured using real-time reversetranscription PCR (qRT-PCR). Differences in the expression of these factors between pterygium and conjunctival specimens were examined, as well as correlations between RNA levels and clinical parameters. mRNA levels for VEGFA and FGF2 were significantly higher in pterygium, compared with conjunctival specimens, whereas the respective differences for other factors examined were statistically not significant. The mRNA levels for VEGFA and FGF2 were also significantly higher in recurrent compared with primary pterygium. Correlations between the mRNA levels and other clinical parameters were statistically not significant for the growth factors examined. The higher levels of FGF2 or VEGFA mRNA in pterygium imply that these factors may be involved in the pathogenesis or clinical behavior of the pterygium, including postoperative recurrence. VEGFA expression may have potential for use in the selective treatment of pterygium with anti-VEGFA agents.

show abstract

“…Pterygium was originally considered an 'ophthalmoheliosis', i.e., a condition closely related to the exposure of the eyes to increased amounts of sunshine which could, through poorly understood mechanisms, result in fibrovascular growth on the ocular surface (2,4). However, during the last decades, several potential mechanisms for pterygium development have been examined, mostly by employing molecular genetic analysis techniques of tissue samples (5)(6)(7)(8)(9)(10). Consequently, insights into the pathogenesis of pterygium were gained through the improved understanding of molecular genetic pathways (5)(6)(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

“…However, during the last decades, several potential mechanisms for pterygium development have been examined, mostly by employing molecular genetic analysis techniques of tissue samples (5)(6)(7)(8)(9)(10). Consequently, insights into the pathogenesis of pterygium were gained through the improved understanding of molecular genetic pathways (5)(6)(7)(8)(9)(10). The advent of commercially available pharmaceutical agents which could, acting on a molecular level, affect important aspects of pterygium clinical behaviour, such as the angiogenesis or cellular proliferation, opens a promising new therapeutic avenue (11,12).…”

Section: Introductionmentioning

confidence: 99%

Pathogenetic mechanisms and treatment options for ophthalmic pterygium: Trends and perspectives (Review)

Detorakis

Spandidos²

2009

Int J Mol Med

145

103

View full text Add to dashboard Cite

Abstract. Pterygium is a fibrovascular lesion of the ocular surface that can display an aggressive clinical behavior and, occasionally, threaten vision. Although there is no consensus on its pathogenesis, recent evidence suggests that it is a proliferative, rather than degenerative condition strongly correlated with exposure to ultraviolet radiation (UVR) of solar light. Molecular genetic alterations reported in association with pterygium include loss of heterozygosity (LOH), point mutations of proto-oncogenes, such as K-ras and alterations in the expression of tumor suppressor genes, such as p53 or p63. Other findings in pterygium include the frequent detection of HPV DNA, ocular surface changes such as the overexpression of various proteins, including defensins and phospolipases D, as well as the up-regulation of growth factors, such as bFGF or VEGF. Although pterygium management has traditionally involved surgery, often enhanced by the use of antimetabolites, recent advancements in the understanding of molecular and biochemical events underlying pterygium pathogenesis may enable the use of less invasive treatment methods.

show abstract

Angiogenesis in pterygium: Morphometric and immunohistochemical study

Cited by 87 publications

References 11 publications

Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1

Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1

Growth factor expression in ophthalmic pterygia and normal conjunctiva

Pathogenetic mechanisms and treatment options for ophthalmic pterygium: Trends and perspectives (Review)

Contact Info

Product

Resources

About